- Email: [email protected]
“Act Early” Resources for Preventing Developmental Delays
“Act Early” Resources for Preventing Developmental Delays
i You can download resources from the website or order materials to be mailed to you at no charge
In an attempt to identify infants and toddlers at risk for autism earlier on, the Centers for Disease Control and Prevention (CDC) and its partners have launched an awareness campaign targeting parents and health care professionals in an effort to increase their understanding of developmental milestones and the importance of acting early when a possible delay is noticed. The earlier a child with a developmental delay receives appropriate assessment and intervention, the more likely he is to reach his full potential. To help prepare the health care community for the anticipated increase in questions and requests for information from parents, CDC has developed a Provider Resource Kit. This kit contains materials to help health care professionals communicate with parents about childhood development. Materials, available in English and in Spanish, include: • exam room posters • informational cards for waiting room displays • fact sheets on age-specific developmental milestones and developmental disorders • other resources Visit the campaign website at www.cdc.gov/actearly to view the campaign
162
AWHONN Lifelines
Volume 9
Issue 2
resources designed for health care professionals—you can download them from the website or order materials to be mailed to you at no charge. Most parents don’t know about developmental milestones. They don’t know when a child should be making eye contact, recognizing and interacting with objects or beginning to imitate words or actions. They simply don’t have the basic information that would allow them to recognize the early signs of a developmental disorder and empower them to act. The “Learn the Signs. Act Early.” campaign aims to help parents identify possible developmental delays and encourage them to discuss concerns with their child’s health care professional. In addition to offering a series of public service announcements, the campaign offers a Parent Kit to those who visit the website at www.cdc.gov/actearly or call the toll-free hotline (800) CDC-INFO. This kit contains materials in English and Spanish, including an informational card with developmental milestones and questions to ask their child’s health care professional, fact sheets on developmental milestones and a growth chart (to be hung on the wall to measure growth and prompt parents to think about corresponding developmental milestones).
of cellular immunity against HIV, although it’s not expected to provide enough data to support immediate licensing of the vaccine for public use, says Margaret (Peggy) Johnston, PhD, who oversees HIV vaccine research at NIAID’s Division of AIDS. The vaccine contains a weakened adenovirus that serves as a carrier for three subtype-B HIV genes. Subtype B is the most prevalent HIV subtype in the regions of the study sites. Adenoviruses are among the main causes of upper respiratory tract ailments such as the common cold. Because the vaccine contains only three HIV genes housed in a weakened adenovirus, study participants cannot become infected with HIV or get a respiratory infection from the vaccine. Organizers are seeking healthy, HIVnegative men and women volunteers between the ages of 18 and 45 who are at an increased risk of acquiring HIV. The researchers plan to enroll a significant number of volunteers from populations particularly hard-hit by AIDS, including African Americans and other ethnic minorities. The trials in North America will take place in the following cities: Atlanta, Boston, Chicago, Denver, Houston, Los Angeles, Miami, New York, Philadelphia, St. Louis, San Francisco, Seattle and Toronto. For more information on enrolling, visit HVTN’s website at www.hvtn.org.
Merck developed the experimental vaccine to stimulate HIVspecific cellular immunity, which prompts the body to produce T cells that kill HIV-infected cells
Volunteers Needed for HIV/AIDS Vaccine Trial large clinical trial of a novel HIV vaccine has begun enrolling volunteers at sites in North America, South America, the Caribbean and Australia. Organizers are seeking 1,500 participants. The trial is co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the pharmaceutical company Merck & Co. Inc. Merck developed the experimental vaccine to stimulate HIV-specific cellular immunity, which prompts the body to produce T cells that kill HIV-infected cells. In previous smaller trials, this vaccine was found to be safe and to induce cellular immune responses against HIV in more than half of volunteers. This proof-of-concept trial is designed to yield vital information on the potential efficacy
A
April | May 2005
Preventing Falls & Other Injuries in Elderly Persons njuries are rising dramatically among the elderly. In 2002, more than 1.45 million Americans ages 65 years and older went to hospital emergency rooms with consumer product–related injuries. According to a new study titled “Special Report: Emergency Room Injuries in Adults 65 and Older,” consumers in that age group are increasingly at risk for product-related injuries in or around the home, especially falls. The report is being announced today to coincide with the kickoff of a major education campaign by the U.S. Consumer Product Safety Commission and the National Safety Council. The special report finds those 75 years and older especially vulnerable. From 1991 to 2002, the number of people 75 and older treated in
I
AWHONN Lifelines
163
i You can download resources from the website or order materials to be mailed to you at no charge
In an attempt to identify infants and toddlers at risk for autism earlier on, the Centers for Disease Control and Prevention (CDC) and its partners have launched an awareness campaign targeting parents and health care professionals in an effort to increase their understanding of developmental milestones and the importance of acting early when a possible delay is noticed. The earlier a child with a developmental delay receives appropriate assessment and intervention, the more likely he is to reach his full potential. To help prepare the health care community for the anticipated increase in questions and requests for information from parents, CDC has developed a Provider Resource Kit. This kit contains materials to help health care professionals communicate with parents about childhood development. Materials, available in English and in Spanish, include: • exam room posters • informational cards for waiting room displays • fact sheets on age-specific developmental milestones and developmental disorders • other resources Visit the campaign website at www.cdc.gov/actearly to view the campaign
162
AWHONN Lifelines
Volume 9
Issue 2
resources designed for health care professionals—you can download them from the website or order materials to be mailed to you at no charge. Most parents don’t know about developmental milestones. They don’t know when a child should be making eye contact, recognizing and interacting with objects or beginning to imitate words or actions. They simply don’t have the basic information that would allow them to recognize the early signs of a developmental disorder and empower them to act. The “Learn the Signs. Act Early.” campaign aims to help parents identify possible developmental delays and encourage them to discuss concerns with their child’s health care professional. In addition to offering a series of public service announcements, the campaign offers a Parent Kit to those who visit the website at www.cdc.gov/actearly or call the toll-free hotline (800) CDC-INFO. This kit contains materials in English and Spanish, including an informational card with developmental milestones and questions to ask their child’s health care professional, fact sheets on developmental milestones and a growth chart (to be hung on the wall to measure growth and prompt parents to think about corresponding developmental milestones).
of cellular immunity against HIV, although it’s not expected to provide enough data to support immediate licensing of the vaccine for public use, says Margaret (Peggy) Johnston, PhD, who oversees HIV vaccine research at NIAID’s Division of AIDS. The vaccine contains a weakened adenovirus that serves as a carrier for three subtype-B HIV genes. Subtype B is the most prevalent HIV subtype in the regions of the study sites. Adenoviruses are among the main causes of upper respiratory tract ailments such as the common cold. Because the vaccine contains only three HIV genes housed in a weakened adenovirus, study participants cannot become infected with HIV or get a respiratory infection from the vaccine. Organizers are seeking healthy, HIVnegative men and women volunteers between the ages of 18 and 45 who are at an increased risk of acquiring HIV. The researchers plan to enroll a significant number of volunteers from populations particularly hard-hit by AIDS, including African Americans and other ethnic minorities. The trials in North America will take place in the following cities: Atlanta, Boston, Chicago, Denver, Houston, Los Angeles, Miami, New York, Philadelphia, St. Louis, San Francisco, Seattle and Toronto. For more information on enrolling, visit HVTN’s website at www.hvtn.org.
Merck developed the experimental vaccine to stimulate HIVspecific cellular immunity, which prompts the body to produce T cells that kill HIV-infected cells
Volunteers Needed for HIV/AIDS Vaccine Trial large clinical trial of a novel HIV vaccine has begun enrolling volunteers at sites in North America, South America, the Caribbean and Australia. Organizers are seeking 1,500 participants. The trial is co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the pharmaceutical company Merck & Co. Inc. Merck developed the experimental vaccine to stimulate HIV-specific cellular immunity, which prompts the body to produce T cells that kill HIV-infected cells. In previous smaller trials, this vaccine was found to be safe and to induce cellular immune responses against HIV in more than half of volunteers. This proof-of-concept trial is designed to yield vital information on the potential efficacy
A
April | May 2005
Preventing Falls & Other Injuries in Elderly Persons njuries are rising dramatically among the elderly. In 2002, more than 1.45 million Americans ages 65 years and older went to hospital emergency rooms with consumer product–related injuries. According to a new study titled “Special Report: Emergency Room Injuries in Adults 65 and Older,” consumers in that age group are increasingly at risk for product-related injuries in or around the home, especially falls. The report is being announced today to coincide with the kickoff of a major education campaign by the U.S. Consumer Product Safety Commission and the National Safety Council. The special report finds those 75 years and older especially vulnerable. From 1991 to 2002, the number of people 75 and older treated in
I
AWHONN Lifelines
163